A 58-year-old man presents to his hepatologist to discuss management of his chronic hepatitis C. He was first diagnosed with hepatitis C genotype 1a infection 1 year ago on routine screening. He was subsequently lost to follow-up due to financial issues and has not undergone hepatitis C therapy. He feels generally fatigued but is otherwise asymptomatic, and he has no evidence of cirrhosis. His hepatitis C viral load today is 150,000 IU/mL, slightly decreased from 200,000 IU/mL 1 year ago. Other than chronic hepatitis C, past medical history is notable for remote intravenous drug use 20 years ago. Review of systems is negative for fevers, arthralgias, abdominal pain, nausea, vomiting, or other symptoms. Vital signs and physical examination are unremarkable. Complete blood count, serum comprehensive metabolic panel, and coagulation tests are normal other than an alanine aminotransferase of 50 U/L and an aspartate aminotransferase of 42 U/L. Which of the following therapies should be considered for this patient?